a Cohort Study of Ischemic Cerebrovascular Disease
ConditionIschaemic Stroke
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXiangya Hospital of Central South University
About this trial
This study aims to establish a multicenter, large-scale, prospective cohort of patients with ischemic stroke. Various biological samples such as blood, feces, and urine are collected to identify biomarkers associated with ischemic stroke. By integrating demographic information, clinical indicators, imaging parameters, and biomarker parameters, the study aims to develop risk assessment, early warning, and prognosis prediction models. Additionally, the study aims to identify key genes and explore relevant signaling pathways related to ischemic stroke.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Clinical diagnosis of ischemic stroke.
Age ≥ 18 years.
Signed informed consent form.
Disqualifiers
Patients with moderate to severe mental disorders or dementia who cannot cooperate to complete the informed consent and follow-up procedures.
Patients with neurological functional impairment caused by conditions such as migraine aura, epilepsy, or other non-ischemic strokes.
Agitated patients who cannot cooperate with imaging examinations.
Pregnant or lactating patients, as well as those planning to become pregnant within 90 days.
Trial population
Continuously enroll hospitalized patients who meet the inclusion criteria
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Intravenous thrombolysis
Other interventionIntravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
Treatment groups
5,000 Participants
are divided into 2 treatment groupsGroup A: those with favorable prognosis1 intervention
Group B: those with unfavorable prognosis1 intervention
Trial outcomes
Primary outcomes
1
Cerebrovascular events
Cerebrovascular events, including ischemic stroke, transient ischemic attack, cerebral hemorrhage, subarachnoid hemorrhage
Time frame
3 months of onset in patients2
mRS scores
Assessing patients' neurological functional impairment status using the mRS score
Time frame
3 months of onset in patientsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov